TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• Arm Holdings falls as CFO stock sale weighs on sentiment
• Jefferies Financial stock slips 3% as Fixed Income, Asset Management revenues fall